A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.

Elaine C SiegfriedLara Wine LeeJonathan M SpergelRandy PrescillaSumeet UppalAnna ColemanAshish BansalSonya L Cyr Brad Shumel

Published in: Pediatric dermatology (2024)

In this case series of dupilumab-treated children with severe AD who received MMR vaccine with or without varicella vaccine, no adverse effects (including vaccine-related infection) were reported within 4 weeks after vaccination. Further studies are warranted to evaluate the safety, tolerability, and immune response to live attenuated vaccines in dupilumab-treated patients.

Keyphrases

atopic dermatitis
newly diagnosed
young adults
ejection fraction
prognostic factors
randomized controlled trial
open label
patient reported outcomes
study protocol